A Phase 4, Multicenter, Open-label Study of Serum Infliximab Concentrations and Efficacy and Safety of Dose Escalation in Pediatric Patients With Inflammatory Bowel Disease
Phase of Trial: Phase IV
Latest Information Update: 02 Aug 2017
At a glance
- Drugs Infliximab (Primary)
- Indications Crohn's disease; Inflammatory bowel diseases; Ulcerative colitis
- Focus Therapeutic Use
- Acronyms ADAPT
- Sponsors Janssen
- 25 Feb 2016 Treatment table revised to include only one maintenance dose instead of two maintenance doses.
- 25 Feb 2016 Planned primary completion date changed from 1 Aug 2016 to 1 Aug 2019, as reported by ClinicalTrials.gov.
- 07 Dec 2015 Status changed from not yet recruiting to recruiting, according to ClinicalTrials.gov record.